5 patents
Utility
Method of Treating Early Stage Dupuytren's Disease
13 Jul 23
The subject invention provides a method of treating an individual afflicted with early stage Dupuytren's disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule.
Jagdeep Nanchahal, Glenn R. Larsen, Marc Feldmann
Filed: 24 Feb 23
Utility
Method of treating dupuytren's disease using a pre-filled syringe
28 Mar 23
The subject invention provides a method of treating an individual afflicted with early stage Dupuytren's disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule.
Jagdeep Nanchahal, Glenn R. Larsen, Marc Feldmann
Filed: 14 Apr 22
Utility
Method of treating a localized fibrotic disorder using an IL-33 antagonist
2 Aug 22
The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient.
Glenn Larsen, Jagdeep Nanchahal, Marc Feldmann
Filed: 9 Dec 19
Utility
Method of Treating Dupuytren's Disease Using A Pre-filled Syringe
28 Jul 22
The subject invention provides a method of treating an individual afflicted with early stage Dupuytren's disease characterized by the presence of one or more nodules on the individual's hand which comprises injecting into each nodule a pharmaceutical composition comprising an amount of an antihuman TNFa antibody or fragment thereof effective to treat the individual, wherein the pharmaceutical composition is in the form of a liquid and between 0.1 ml and 0.6 ml of the composition is injected into each nodule.
Jagdeep Nanchahal, Glenn R. Larsen, Marc Feldmann
Filed: 14 Apr 22
Utility
Method of Treating a Localized Fibrotic Disorder Using a TNF Receptor 2 Antagonist
16 Dec 21
The subject invention provides a method of treating a patient suffering from a localized fibrotic condition which comprises administering to the patient an amount of an IL-33 antagonist effective to treat the patient.
Glenn Larsen, Jagdeep Nanchahal, Marc Feldmann
Filed: 29 Jul 21
- Prev
- 1
- Next
Patents are sorted by USPTO publication date, most recent first